Settlement Finalized Between Mylan, Feds Over EpiPen Overcharges To Medicaid
The $465 million settlement announced Thursday by the Department of Justice resolves claims that Mylan avoided paying rebates to the government by improperly classifying the EpiPen as a generic drug. Mylan and its auto-injector product have been at the center of the national debate over prescription drug costs.
EpiPen Maker Finalizes Settlement For Government Overcharges
EpiPen maker Mylan has finalized a $465 million government agreement settling allegations it overbilled Medicaid for its emergency allergy injectors for a decade — charges brought after rival Sanofi filed a whistleblower lawsuit and tipped off the government. It’s the second settlement with the Department of Justice that Mylan has made since 2009 for allegedly overcharging the government for its medicines. (Johnson, 8/18)
Mylan $465M EpiPen Settlement Finalized
The drugmaker raised EpiPen prices by roughly 400% between 2010 and 2016, according to federal investigators. EpiPen is a disposable, pre-filled injector that administers epinephrine to counteract severe allergic reactions. (McCoy, 8/17)
EpiPen Maker Mylan To Settle On Claims It Overcharged Taxpayers
Lawmakers slammed the federal agencies on Thursday for letting Mylan get off the hook too easily with the settlement. Sen. Richard Blumenthal (D-Conn.) called it “completely insufficient,” and Sen. Chuck Grassley (R-Iowa) cast is as “disappointing” in statements. Mylan, meanwhile, called the settlement, “the right course of action,” and said that the product has been reclassified under Medicaid as of April 1. (Swetlitz, 8/17)